Mavacamten HCM denied as non-formulary by Aetna?

Aetna's specific coverage criteria for mavacamten hcm are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Denies Mavacamten as Non-Formulary — and Why You Can Appeal

Mavacamten is approved for symptomatic obstructive hypertrophic cardiomyopathy (oHCM). As a relatively newer specialty drug, mavacamten may sit on a restricted formulary tier or be entirely excluded from some Aetna plan formularies. A non-formulary denial does not mean the drug is not medically appropriate — it means the plan has not included it in its standard covered drug list, or has placed it at a tier requiring additional justification. Most plans must provide a formulary exception process for non-formulary drugs when a formulary alternative is clinically inappropriate.

## Why Non-Formulary Denials Are Appealable

Under federal law and standard plan documents, enrollees have the right to request a formulary exception when no formulary drug is medically appropriate for their condition. Because mavacamten is the only FDA-approved cardiac myosin inhibitor for oHCM and acts through a mechanism not shared by any formulary alternative, the standard exception basis — "no formulary drug is clinically appropriate" — typically applies. The appeal process and the formulary exception process can often be pursued simultaneously.

## Federal Appeal Framework

• Formulary exception request: File a formulary exception alongside or before the formal appeal. This is a separate administrative process and may resolve the issue faster.
• Internal appeal: Submit within the window in your denial letter. Request Aetna's full formulary exception criteria and the specific formulary alternatives it considered.
• External review (ACA §2719): Available after internal remedies are exhausted, generally within four months of final denial for non-grandfathered plan members.
• ERISA §503: Employer-plan members have full-and-fair review rights and may request all documents relied upon in the denial.
• Expedited review: Available when delay poses serious health risk.

## Documentation to Gather

• Diagnosis confirmation: Specialist records confirming symptomatic oHCM and current clinical status.
• Formulary alternative assessment: Documentation from the prescriber explaining why each formulary alternative for oHCM (typically rate-controlling agents) is inadequate or not therapeutically equivalent to mavacamten given this patient's specific clinical situation.
• Prescriber medical-necessity letter: A letter from the treating cardiologist confirming the unique mechanism of mavacamten, why it is the only appropriate agent for this patient, and alignment with current cardiology society guidelines.
• Prior therapy records: Documentation of trials of formulary alternatives, with dates and outcomes, to support the exception basis.

## Criteria-Mapping Structure

Request Aetna's formulary exception criteria and the specific formulary alternatives evaluated. Then map:

| Exception Criterion | Supporting Documentation | |---|---| | No formulary drug is therapeutically equivalent | [Prescriber letter — distinct mechanism, no approved equivalent] | | Formulary alternatives clinically inappropriate or tried/failed | [Prior therapy records with dates and outcomes] | | FDA-approved indication matches patient's diagnosis | [Specialist note, ICD code] | | Prescribing provider credentials | [Cardiologist / HCM specialist note] |

A formulary exception paired with a strong prescriber letter resolves the majority of non-formulary denials for drugs without a true therapeutic equivalent.